PL4356969T3 - Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu zakażenia ortomyksowirusami - Google Patents
Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu zakażenia ortomyksowirusamiInfo
- Publication number
- PL4356969T3 PL4356969T3 PL23217305.4T PL23217305T PL4356969T3 PL 4356969 T3 PL4356969 T3 PL 4356969T3 PL 23217305 T PL23217305 T PL 23217305T PL 4356969 T3 PL4356969 T3 PL 4356969T3
- Authority
- PL
- Poland
- Prior art keywords
- orthomyxoviral
- infections
- treatment
- compounds useful
- pyridazinone compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380712P | 2016-08-29 | 2016-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4356969T3 true PL4356969T3 (pl) | 2025-10-20 |
Family
ID=59923494
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17771587T PL3504214T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
| PL23217305.4T PL4356969T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu zakażenia ortomyksowirusami |
| PL20210329.7T PL3848372T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17771587T PL3504214T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20210329.7T PL3848372T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10160764B2 (pl) |
| EP (4) | EP4356969B1 (pl) |
| JP (3) | JP7221861B2 (pl) |
| CN (2) | CN109863151B (pl) |
| AR (1) | AR109438A1 (pl) |
| CA (1) | CA3035302A1 (pl) |
| DK (1) | DK4356969T3 (pl) |
| ES (3) | ES2859510T3 (pl) |
| FI (1) | FI4356969T3 (pl) |
| HR (1) | HRP20250885T1 (pl) |
| HU (1) | HUE072776T2 (pl) |
| JO (1) | JOP20170169A1 (pl) |
| LT (1) | LT4356969T (pl) |
| MX (1) | MX383124B (pl) |
| PL (3) | PL3504214T3 (pl) |
| PT (3) | PT4356969T (pl) |
| SI (3) | SI3504214T1 (pl) |
| TW (3) | TW202517646A (pl) |
| UY (2) | UY40872A (pl) |
| WO (1) | WO2018042303A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102323515B1 (ko) * | 2013-09-12 | 2021-11-05 | 얀센 바이오파마, 인코퍼레이트. | 아자-피리돈 화합물 및 이의 용도 |
| JP6323860B2 (ja) | 2015-12-15 | 2018-05-16 | 塩野義製薬株式会社 | キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬 |
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| AU2017310774B2 (en) | 2016-08-10 | 2023-01-19 | Shionogi & Co., Ltd. | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| CN111848616B (zh) | 2018-01-17 | 2021-11-23 | 江西彩石医药科技有限公司 | 吡啶酮衍生物及其用于制备抗流感病毒药物的用途 |
| EA202091696A1 (ru) * | 2018-02-28 | 2021-01-27 | Новартис Аг | ПРОИЗВОДНЫЕ 10-(ДИ(ФЕНИЛ)МЕТИЛ)-4-ГИДРОКСИ-8,9,9a,10-ТЕТРАГИДРО-7H-ПИРРОЛО[1',2':4,5]ПИРАЗИНО[1,2-b]ПИРИДАЗИН-3,5-ДИОНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ РЕПЛИКАЦИИ ОРТОМИКСОВИРУСА ДЛЯ ЛЕЧЕНИЯ ГРИППА |
| CN108440564B (zh) * | 2018-04-11 | 2019-08-06 | 安帝康（无锡）生物科技有限公司 | 被取代的多环氨基甲酰基吡啶酮衍生物及其前药 |
| KR20210074329A (ko) * | 2018-10-10 | 2021-06-21 | 얀센 바이오파마, 인코퍼레이트. | 매크로사이클릭 플루 엔도뉴클레아제 억제제 |
| CN111909174B (zh) | 2019-05-08 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物的晶型及制备方法和应用 |
| WO2021129602A1 (zh) * | 2019-12-23 | 2021-07-01 | 石家庄迪斯凯威医药科技有限公司 | 取代的多环化合物及其药物组合物和用途 |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| WO2022105669A1 (zh) * | 2020-11-17 | 2022-05-27 | 南京明德新药研发有限公司 | 含Se大环类化合物 |
| WO2024228401A1 (ja) * | 2023-05-02 | 2024-11-07 | 国立大学法人 大分大学 | 新型コロナウイルス感染症の処置または予防用医薬としての置換三環式複素環化合物 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2225112A (en) | 1938-07-09 | 1940-12-17 | Wright Aeronautical Corp | Air cleaner |
| GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
| AUPM354694A0 (en) | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
| DK3042894T1 (da) | 2001-08-10 | 2016-11-07 | Shionogi & Co | Antiviralt middel |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| CA2557926A1 (en) | 2004-03-09 | 2005-09-22 | Monica Donghi | Hiv integrase inhibitors |
| FR2901795A1 (fr) | 2006-05-30 | 2007-12-07 | Fourtillan Snc | Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique |
| MX2011004636A (es) | 2008-10-31 | 2011-06-20 | Shionogi & Co | Cefarosporinas que tienen un grupo catecol. |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| WO2010110231A1 (ja) | 2009-03-26 | 2010-09-30 | 塩野義製薬株式会社 | 置換された３－ヒドロキシ－４－ピリドン誘導体 |
| DK2444400T3 (en) | 2009-06-15 | 2018-06-18 | Shionogi & Co | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE |
| CA2783258A1 (en) | 2009-12-23 | 2011-06-30 | Elan Pharmaceuticals, Inc. | Pteridinones as inhibitors of polo-like kinase |
| US8541407B2 (en) | 2010-03-31 | 2013-09-24 | Arqule, Inc. | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CA2812363C (en) | 2010-09-24 | 2019-04-02 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
| WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| CA2851218A1 (en) | 2011-10-12 | 2013-04-18 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
| ES2604766T3 (es) | 2012-09-20 | 2017-03-09 | Celltrion, Inc. | Derivado de dolastatina-10, procedimiento de producción del mismo y composición de fármaco anticanceroso que contiene el mismo |
| PE20151722A1 (es) | 2013-01-08 | 2015-11-19 | European Molecular Biology Lab Embl | Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral |
| PH12021550330A1 (en) | 2013-08-21 | 2022-09-28 | Janssen Biopharma Inc | Antiviral compounds |
| WO2015038665A1 (en) | 2013-09-11 | 2015-03-19 | University Of Southern California | A composition of stem cells having highly expressed fas ligand |
| KR102323515B1 (ko) | 2013-09-12 | 2021-11-05 | 얀센 바이오파마, 인코퍼레이트. | 아자-피리돈 화합물 및 이의 용도 |
| LT3030549T (lt) | 2013-09-12 | 2019-06-25 | Janssen Biopharma, Inc. | Piridazinono junginiai ir jų panaudojimas |
| JP2017521424A (ja) | 2014-07-07 | 2017-08-03 | ザヴィラ ファーマシューティカルズ ゲーエムベーハー | ウイルス疾患の治療、改善又は予防におけるジヒドロピリドピラジン−１，８−ジオン及びそれらの使用 |
| EA036776B1 (ru) | 2015-03-11 | 2020-12-21 | Янссен Байофарма, Инк. | Соединения азапиридона и способы их применения |
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| WO2017156407A1 (en) | 2016-03-10 | 2017-09-14 | Alios Biopharma, Inc. | Method of preparing aza-pyridone compounds |
| BR112018077136A2 (pt) | 2016-07-01 | 2019-04-30 | G1 Therapeutics, Inc. | composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis. |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| AU2017310774B2 (en) | 2016-08-10 | 2023-01-19 | Shionogi & Co., Ltd. | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| JP2019059697A (ja) * | 2017-09-28 | 2019-04-18 | 塩野義製薬株式会社 | 置換された多環性ピリダジン誘導体およびそのプロドラッグ |
| CN111848616B (zh) | 2018-01-17 | 2021-11-23 | 江西彩石医药科技有限公司 | 吡啶酮衍生物及其用于制备抗流感病毒药物的用途 |
| CN110041327B (zh) | 2018-01-17 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
| RU2020131405A (ru) | 2018-02-28 | 2022-03-24 | Джапан Тобакко Инк. | Сконденсированные с насыщенным кольцом дигидропиримидиноновые или дигидротриазиноновые соединения и их применение в фармацевтике |
| EA202091696A1 (ru) | 2018-02-28 | 2021-01-27 | Новартис Аг | ПРОИЗВОДНЫЕ 10-(ДИ(ФЕНИЛ)МЕТИЛ)-4-ГИДРОКСИ-8,9,9a,10-ТЕТРАГИДРО-7H-ПИРРОЛО[1',2':4,5]ПИРАЗИНО[1,2-b]ПИРИДАЗИН-3,5-ДИОНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ РЕПЛИКАЦИИ ОРТОМИКСОВИРУСА ДЛЯ ЛЕЧЕНИЯ ГРИППА |
| WO2019166432A1 (en) | 2018-02-28 | 2019-09-06 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |
| SG11202007117RA (en) | 2018-02-28 | 2020-08-28 | Japan Tobacco Inc | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof |
-
2017
- 2017-08-24 JO JOP/2017/0169A patent/JOP20170169A1/ar unknown
- 2017-08-25 SI SI201730650T patent/SI3504214T1/sl unknown
- 2017-08-25 PT PT232173054T patent/PT4356969T/pt unknown
- 2017-08-25 CN CN201780065653.XA patent/CN109863151B/zh active Active
- 2017-08-25 EP EP23217305.4A patent/EP4356969B1/en active Active
- 2017-08-25 CA CA3035302A patent/CA3035302A1/en active Pending
- 2017-08-25 EP EP25187556.3A patent/EP4640279A3/en active Pending
- 2017-08-25 DK DK23217305.4T patent/DK4356969T3/da active
- 2017-08-25 EP EP20210329.7A patent/EP3848372B1/en active Active
- 2017-08-25 MX MX2019002438A patent/MX383124B/es unknown
- 2017-08-25 US US15/686,652 patent/US10160764B2/en active Active
- 2017-08-25 PL PL17771587T patent/PL3504214T3/pl unknown
- 2017-08-25 PL PL23217305.4T patent/PL4356969T3/pl unknown
- 2017-08-25 ES ES17771587T patent/ES2859510T3/es active Active
- 2017-08-25 FI FIEP23217305.4T patent/FI4356969T3/fi active
- 2017-08-25 ES ES23217305T patent/ES3042460T3/es active Active
- 2017-08-25 SI SI201731620T patent/SI4356969T1/sl unknown
- 2017-08-25 CN CN202110956692.7A patent/CN113683614B/zh active Active
- 2017-08-25 PT PT202103297T patent/PT3848372T/pt unknown
- 2017-08-25 HU HUE23217305A patent/HUE072776T2/hu unknown
- 2017-08-25 SI SI201731493T patent/SI3848372T1/sl unknown
- 2017-08-25 ES ES20210329T patent/ES2974494T3/es active Active
- 2017-08-25 HR HRP20250885TT patent/HRP20250885T1/hr unknown
- 2017-08-25 JP JP2019511749A patent/JP7221861B2/ja active Active
- 2017-08-25 US US16/328,616 patent/US11098051B2/en active Active
- 2017-08-25 WO PCT/IB2017/055137 patent/WO2018042303A1/en not_active Ceased
- 2017-08-25 EP EP17771587.7A patent/EP3504214B1/en active Active
- 2017-08-25 PL PL20210329.7T patent/PL3848372T3/pl unknown
- 2017-08-25 PT PT177715877T patent/PT3504214T/pt unknown
- 2017-08-25 LT LTEP23217305.4T patent/LT4356969T/lt unknown
- 2017-08-28 TW TW113134345A patent/TW202517646A/zh unknown
- 2017-08-28 TW TW106129086A patent/TWI803467B/zh active
- 2017-08-28 TW TW112101158A patent/TWI869757B/zh active
- 2017-08-28 UY UY0001040872A patent/UY40872A/es not_active Application Discontinuation
- 2017-08-28 UY UY0001037378A patent/UY37378A/es active IP Right Grant
- 2017-08-29 AR ARP170102385A patent/AR109438A1/es active IP Right Grant
-
2021
- 2021-07-13 US US17/374,237 patent/US11912715B2/en active Active
-
2022
- 2022-11-22 JP JP2022186394A patent/JP2023027102A/ja not_active Withdrawn
-
2024
- 2024-06-13 US US18/743,020 patent/US20250011334A1/en active Pending
-
2025
- 2025-01-23 JP JP2025009843A patent/JP2025081322A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT4356969T (lt) | Kondensuoti tricikliniai piridazinono junginiai, naudotini ortomiksovirusinių infekcijų gydymui | |
| HUS2500039I1 (hu) | Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra | |
| IL269354A (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| IL263972A (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| EP3922634C0 (en) | SUBSTITUTED PYRROLIZINE COMPOUNDS AND THEIR APPLICATIONS | |
| SI3347352T1 (sl) | Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV | |
| MA45192A (fr) | Traitement d'association | |
| DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| HUE053704T2 (hu) | 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére | |
| DK3511328T3 (da) | Organiske monobactam-forbindelser til behandling af bakterieinfektioner | |
| DK3490582T3 (da) | Sammensætninger til anvendelse i behandling af myelofibrose | |
| HRP20251450T1 (hr) | Beta-d-2'-dezoksi-2'alfa-fluoro-2'-beta-c-supstituirani-2-modificirani-n6-supstituirani purinski nukleotidi za liječenje hcv | |
| IL247111A0 (en) | Preventive or therapeutic agent for kidney disease | |
| IL271863B (en) | Compounds and use thereof for the treatment of microbial infections | |
| DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
| EP3548045C0 (en) | COMPOSITIONS FOR USE IN THE TREATMENT OF UROGENITAL INFECTION | |
| EP3661919A4 (en) | SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| HUE058314T2 (hu) | Pridopidin alkalmazása Rett-szindróma kezelésére | |
| CY2024037I2 (el) | Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων | |
| EP3523284A4 (en) | NUCLEOBASE DIVALENT COMPOUNDS AND THEIR USES | |
| DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
| EP3493823C0 (en) | POSTBIOTIC BASED COMPOUND FOR THE TREATMENT OF OCULAR INFLAMMATION | |
| DK3423060T3 (da) | Imatinib til anvendelse til behandling af slagtilfælde |